INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity ® (dulaglutide) met its primary efficacy endpoint of ...

TORONTO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- On September 11, 2020, Health Canada approved Trulicity® (dulaglutide) ... Two crossed lines that form an 'X'.

Lilly began its HCP marketing push for Trulicity last year, first targeting endocrinologists in November and then primary care providers in February. The drugmaker spent $5.49 million on professional ...

Trulicity is a prescription drug used to manage blood sugar and lower risk of heart problems in people with type 2 diabetes. Learn about its dosages and more.

Shares of Eli Lilly & Co. fell 2.4% in premarket trade on Monday after a randomized control trial showed that diabetes drug Trulicity lowered the risk of major cardiovascular events in patients ...

The win puts Trulicity in a small group of GLP-1 drugs that have posted heart-helping benefits for patients. The thing is, Novo Nordisk’s weekly Ozempic—whose active ingredient, semaglutide ...

Lilly expands Trulicity marketing push, lowers 2015 guidance . The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take ...

This decision makes Eli Lilly and Company's (NYSE: LLY) Trulicity the first and only type 2 diabetes medicine approved to reduce the risk of MACE for both primary and secondary prevention populations.

With a market cap of $775.6 billion, Eli Lilly and Company (LLY) is a global biopharmaceutical leader with leading products in diabetes (Trulicity, Mounjaro), oncology (Verzenio, Erbitux) and ...

RELATED: Trulicity Pen Approved for Type 2 Diabetes Trulicity is available as 0.75 and 1.5mg single-use pens in 4-count cartons. For more information call (800) 545-5979 or visit Trulicity.com .